---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114810"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:35:05.705127+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix invests up to ~$3.44M in Cannasoul Analytics for preferred shares and convertible notes

## Summary
- Initial investment: $562,770 for 12,737 Series A preferred shares (5% stake) at $44.1550/share.
- Initial convertible note of $1.44M; up to $2M in milestone notes subject to Cannasoul revenue/expense goals.
- Synaptogenix gets 3 of 7 board seats, veto power on 4th, preemptive rights, and veto over major transactions.
- Collaboration agreement to form joint research committee for cannabinoid compounds from Technion lab.
- If Cannasoul misses milestones, investor loses board rights and preferred shares may be converted to ordinary shares.

## SEC filing metadata
- accession: 0001104659-23-114810
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465923114810/0001104659-23-114810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465923114810/tm2329972d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114810
- JSON: https://secwatch.observer/filing/0001104659-23-114810.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114810.txt

## Key facts
- Material Agreements
  TAO Synergies Inc. entered into Collaboration Agreement with Cannasoul Analytics Ltd. (effective 2023-10-31).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Cannasoul Analytics Ltd.
  - Effective: 2023-10-31
  source text: Pursuant to a collaboration agreement entered into by the Company and Cannasoul on October 31, 2023 (the “Collaboration Agreement”), the parties agreed to form a joint research committee with equal representation from the Company and Cannasoul (the “JRC”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465923114810/0001104659-23-114810-index.htm
- Material Agreements
  TAO Synergies Inc. entered into Purchase Agreement with Cannasoul Analytics Ltd. (effective 2023-10-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Cannasoul Analytics Ltd.
  - Effective: 2023-10-31
  source text: On October 31, 2023, Synaptogenix, Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with Cannasoul Analytics Ltd. (“Cannasoul”), pursuant to which the Company agreed to purchase from Cannasoul (i) 12,737 shares of Cannasoul’s Series A preferred shares, no par value per share (the “Preferred Shares”), at a price of $44.1550 per Preferred Share and (ii) a convertible preferred note in an aggregate amount of up to $1,437,598.49 (the “Initial Convertible Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465923114810/0001104659-23-114810-index.htm
- Material Agreements
  TAO Synergies Inc. entered into Investor Rights Agreement with Cannasoul Analytics Ltd., the founders of Cannasoul and certain investors in Cannasoul (effective 2023-10-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Cannasoul Analytics Ltd., the founders of Cannasoul and certain investors in Cannasoul
  - Effective: 2023-10-31
  source text: Also on October 31, 2023, the Company entered into an investor rights agreement (the “Investor Rights Agreement”) with Cannasoul, the founders of Cannasoul and certain investors in Cannasoul (the Company and the other investors collectively, the “Investors”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465923114810/0001104659-23-114810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.